Market Access & Commercial Strategy
Market access consulting positions products for reimbursement and sustainable commercial success. Speyside Health builds HTA strategy and evidence plans, assesses country readiness and innovative funding routes, and designs payer engagement programmes, integrated with the policy and political environment that ultimately determines whether a product reaches patients.
Our medical affairs services
We work across the therapeutic landscape, with documented depth in the areas below. Each groups the specific conditions our teams have delivered on:
HTA strategy and evidence planning
submission sequencing, evidence requirements and value narratives for reimbursement in evolving HTA systems.
Country readiness and archetypes
assessing where each market sits on access maturity and grouping markets by the barriers that matter.
Innovative funding and financing assessment
identifying alternative financing and reimbursement routes where conventional pathways fall short.
Payer engagement programmes
that build the value narrative with the institutions making access decisions.
Integrated policy and commercial plans
access strategy aligned to the political environment, because in our markets pricing and reimbursement are policy outcomes as much as commercial ones.
Market prioritization and launch sequencing
which markets to enter now, later or not at all, with country heatmaps and risk registers.
How does market access differ in emerging markets?
HTA systems in CEE, LATAM, the Middle East and much of Asia are newer, faster-moving and more politically inflected than the established Western European agencies. Timelines published on paper rarely match reality. Access strategy in these markets requires knowing how the assessing institutions actually work, which is intelligence you get from people in the system, not from published guidance.
Proof Point
Example: Hungary & CEE
market access roadmap for a rare-disease biotech, HTA submission sequencing, stakeholder priorities and realistic timelines, grounded in interviews with former health-authority officials.
Proof Point
Example: China
PCSK9 inhibitor pre-launch strategy, feasibility, impact, cost and timelines, supporting a successful launch aligned to the reimbursement landscape.
Proof Point
Example: Japan
ischemic stroke quality landscape scan across 16 workstreams, mapping endpoints to access decisions under MHLW’s ICER framework.
FAQ
FAQ answers to be drafted at ~60–100 words each, answer-first; mark up with FAQPage schema at build.
FAQ answers to be drafted at ~60–100 words each, answer-first; mark up with FAQPage schema at build.
FAQ answers to be drafted at ~60–100 words each, answer-first; mark up with FAQPage schema at build.